The Relationships between HER2 Overexpression and DCIS Characteristics

Area of Science:

• Oncology
• Pathology
• Genetics

Background:

• Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer precursor.
• HER2 overexpression is a known factor in invasive breast cancer prognosis.
• The prognostic significance of HER2 in DCIS requires further elucidation.

Purpose of the Study:

• To investigate the correlation between HER2 overexpression and prognostic factors in DCIS.
• To assess the recurrence risk associated with HER2 status in DCIS patients.
• To determine if HER2 testing can guide treatment decisions for DCIS.

Main Methods:

• Evaluation of 48 DCIS cases based on HER2 amplification status.
• Immunohistochemistry used to assess HER2, Ki67, estrogen receptor (ER), and progesterone receptor (PgR) expression.
• Histopathological variables including nuclear grade and "cancerization of lobules" were analyzed.
• Comparison of recurrence risk factors between HER2-positive and HER2-negative DCIS groups.

Main Results:

• HER2-positive DCIS was significantly associated with younger patient age (p = 0.002).
• HER2-positive DCIS correlated with adverse prognostic factors: high nuclear grade (p < 0.001), high Ki67 (p = 0.003), low ER/PgR (p < 0.001), and "cancerization of lobules" (p = 0.049).
• A high risk of recurrence was hypothesized for HER2-positive DCIS.

Conclusions:

• HER2 amplification in DCIS is more frequent in younger patients.
• HER2-positive DCIS is associated with histopathological predictors of recurrence.
• HER2 testing in DCIS may aid clinicians in selecting optimal patient treatments.